AMERICAN REGENT, INC.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Established
- 1967-01-01
- Employees
- 501
- Market Cap
- -
Safety and Efficacy of a Hematinic Agent in the Treatment of Postpartum Patients
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2006-07-20
- Last Posted Date
- 2018-02-20
- Lead Sponsor
- American Regent, Inc.
- Target Recruit Count
- 291
- Registration Number
- NCT00354484
- Locations
- 🇺🇸
Luitpold Pharmaceuticals, Norristown, Pennsylvania, United States
Long Term Safety Study of (VIT45) Extension Study: Treatment of Anemia in Non-Dialysis Dependent Chronic Kidney Disease
- First Posted Date
- 2006-04-24
- Last Posted Date
- 2018-02-20
- Lead Sponsor
- American Regent, Inc.
- Target Recruit Count
- 145
- Registration Number
- NCT00317226
- Locations
- 🇺🇸
Luitpold Pharmaceuticals Inc., Norristown, Pennsylvania, United States
VIT45 Versus Oral Iron in the Treatment of Anemia in Non-Dialysis Dependent Chronic Kidney Disease
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2006-04-24
- Last Posted Date
- 2018-02-20
- Lead Sponsor
- American Regent, Inc.
- Target Recruit Count
- 255
- Registration Number
- NCT00317239
- Locations
- 🇺🇸
Luitpold Pharmaceuticals, Norristown, Pennsylvania, United States
Taxoprexin Treatment for Advanced Skin Melanoma
Phase 2
Completed
- Conditions
- First Posted Date
- 2005-11-07
- Last Posted Date
- 2018-01-24
- Lead Sponsor
- American Regent, Inc.
- Target Recruit Count
- 30
- Registration Number
- NCT00249262
Taxoprexin® Treatment for Advanced Eye Melanoma
Phase 2
Completed
- Conditions
- First Posted Date
- 2005-10-27
- Last Posted Date
- 2018-01-24
- Lead Sponsor
- American Regent, Inc.
- Target Recruit Count
- 30
- Registration Number
- NCT00244816
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
Taxoprexin Plus Carboplatin Treatment for Advanced Lung Cancer
- First Posted Date
- 2005-10-25
- Last Posted Date
- 2018-01-26
- Lead Sponsor
- American Regent, Inc.
- Target Recruit Count
- 519
- Registration Number
- NCT00243867
- Locations
- 🇺🇸
US Oncology, Dallas, Texas, United States
Pharmacokinetic Study of Intravenous Iron Sucrose in Adolescents on Hemodialysis or Peritoneal Dialysis Receiving Epoetin
Phase 4
Completed
- Conditions
- First Posted Date
- 2005-10-17
- Last Posted Date
- 2018-01-24
- Lead Sponsor
- American Regent, Inc.
- Target Recruit Count
- 8
- Registration Number
- NCT00239616
Safety and Efficacy of Iron Sucrose in Children
Phase 4
Completed
- Conditions
- Interventions
- First Posted Date
- 2005-10-17
- Last Posted Date
- 2021-11-17
- Lead Sponsor
- American Regent, Inc.
- Target Recruit Count
- 141
- Registration Number
- NCT00239642
- Locations
- 🇺🇸
Luitpold Pharmaceutials, Norristown, Pennsylvania, United States
Efficacy and Safety of Venofer (Iron Sucrose Injection USP) in Patients Receiving Peritoneal Dialysis
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2005-10-12
- Last Posted Date
- 2021-05-19
- Lead Sponsor
- American Regent, Inc.
- Target Recruit Count
- 121
- Registration Number
- NCT00236938
Comparison of Safety and Efficacy of Intravenous Iron Versus Oral Iron in Chronic Renal Failure Subjects With Anemia
- First Posted Date
- 2005-10-12
- Last Posted Date
- 2020-10-06
- Lead Sponsor
- American Regent, Inc.
- Target Recruit Count
- 182
- Registration Number
- NCT00236977
- Locations
- 🇺🇸
Luitpold Pharmaceuticals, Valley Forge, Pennsylvania, United States
© Copyright 2024. All Rights Reserved by MedPath